ChangE From Any Systemic psoriasiS therapY to Raptiva

Summary

To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.

Timeline

Start

2008-01

Primary completion

2009-04

Completion

2009-04

Outcome

Outcome not reported

Stopped: “The study was terminated after the European Medicines Agency recommended to suspend the marketing authorisation of Raptiva in the European Union”

Drugs

Indications